# Dyno Therapeutics

> AI-designed AAV capsids for gene therapy — CapsidMap platform partnered with Novartis, Sarepta, Roche.

## Why it is interesting

a16z-led $100M Series A with Lux and CRV — a gene-delivery bottleneck play as pharma outsources capsid engineering.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, ai-ml
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (May 2021): $100M led by a16z; Lux Capital and CRV participated (Dyno press)
- Seed: Polaris and CRV founding investors (company press)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/lux-capital
- https://venturecapitaltracker.com/fund/crv

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/dyno-therapeutics